PerkinElmer, Inc. (PKI)
|Net Income (ttm)||631.71M|
|Ex-Dividend Date||Jan 19, 2023|
|Day's Range||137.95 - 141|
|52-Week Range||113.46 - 203.16|
|Price Target||160.69 (+15.4%)|
|Earnings Date||Nov 8, 2022|
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technol... [Read more]
In 2021, PerkinElmer's revenue was $5.07 billion, an increase of 33.95% compared to the previous year's $3.78 billion. Earnings were $943.16 million, an increase of 29.57%.Financial Statements
According to 19 analysts, the average rating for PKI stock is "Buy." The 12-month stock price forecast is 160.69, which is an increase of 15.36% from the latest price.
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
WALTHAM, Mass.--( BUSINESS WIRE )--PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detectio...
PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screenin...
WALTHAM, Mass.--( BUSINESS WIRE )--PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has autho...
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.03% and 30.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH
Bill Kullback Brings Proven Track Record of Scaling Companies for Successful Outcomes SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnosti...
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PerkinElmer said Monday it expects organic sales and adjusted profit to top its previous third-quarter expectations, and PKI stock jumped. The post PerkinElmer Sweetens Its Outlook And Shares Surge, But...
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and PerkinElmer (PKI) are gaining from strong life science, pharmaceutical and academic end-market demand...
PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kin...
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
PerkinElmer's Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculo...
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer's (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the aut...
Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?